Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus

• Published in: Clinical rheumatology Vol. 23; no. 3; pp. 252 - 255
• Main Authors: Hoshi, Ken-ichi, Matsuda, Masayuki, Ishikawa, Mariko, Mitsuhashi, Shigeaki, Gono, Takahisa, Hashimoto, Takao, Ikeda, Shu-ichi
• Format: Journal Article
• Language: English
• Published: Germany Springer Nature B.V 01.06.2004
• Subjects: Adrenal Cortex Hormones - therapeutic use; Adult; Autoimmune diseases; Female; Hemorrhage; Hemorrhage - immunology; Hemorrhage - therapy; Humans; Immunoglobulins, Intravenous - therapeutic use; Immunosuppressive Agents - therapeutic use; Lung Diseases - immunology; Lung Diseases - therapy; Lupus; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - immunology; Lupus Erythematosus, Systemic - therapy; Plasmapheresis; Tacrolimus - therapeutic use; Treatment Outcome
• ISSN: 0770-3198; 1434-9949
• DOI: 10.1007/s10067-003-0859-2

We report a patient with systemic lupus erythematosus (SLE) who developed fulminant pulmonary hemorrhage. This patient also showed liver dysfunction, bicytopenia and hyperferritinemia, with an increase in serum levels of interleukin (IL)-1 beta, IL-6 and tumor necrosis factor-alpha (TNF-alpha) at the onset of pulmonary symptoms, probably indicating an associated hemophagocytic syndrome. Despite an acute progressive course temporarily requiring mechanical ventilation the patient was successfully treated with continuous drip infusion of tacrolimus, plasmapheresis and intravenous high-dose immunoglobulin and corticosteroid. In this patient increased inflammatory cytokines ascribable to activation of macrophages and/or helper T cells were considered to play an important role in the pathogenesis of the pulmonary hemorrhage. Because this complication is frequently fatal in SLE, intensive therapy, including immunosuppressants and plasmapheresis, should be actively considered as early as possible after onset.